Tyr602
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr602  -  EphB2 (mouse)

Site Information
IyIDPFtyEDPNEAV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448327

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 8 ) , mutation of modification site ( 10 , 11 ) , phospho-antibody ( 9 )
Disease tissue studied:
testicular cancer ( 2 )
Relevant cell line - cell type - tissue:
'neuron, cortical'-brain ( 9 ) , 293 (epithelial) ( 11 ) , 3T3 (fibroblast) ( 11 ) , C2C12-D (muscle cell) ( 5 , 6 ) , COS (fibroblast) ( 11 ) , HEK293T (epithelial) ( 9 ) , MEF (fibroblast) ( 3 , 4 ) , MEF (fibroblast) [PTP1B (mouse), homozygous knockout] ( 3 ) , NG108-15 (neuron) [EphB2 (mouse), transfection] ( 8 ) , NG108-15 (neuron) ( 10 ) , P19 (testicular) ( 2 )

Upstream Regulation
Regulatory protein:
EphB2 (mouse) ( 10 )
Kinases, in vitro:
EphB2 (mouse) ( 7 , 10 )
Treatments:
ephrin_B1 ( 9 , 10 )

Downstream Regulation
Effects of modification on EphB2:
enzymatic activity, induced ( 7 , 10 , 11 ) , molecular association, regulation ( 9 , 11 )
Effects of modification on biological processes:
cell adhesion, altered ( 11 ) , cytoskeletal reorganization ( 10 , 11 )
Induce interaction with:
NMDAR1 (mouse) ( 9 ) , RASA1 (mouse) ( 11 ) , Src iso1 (mouse) ( 11 )

References 

1

Zhou J (2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

2

Zhou J (2010) CST Curation Set: 9109; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

3

Mertins P, et al. (2008) Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-77
18515860   Curated Info

4

Luo W, et al. (2008) Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res 7, 3447-60
18563927   Curated Info

5

Guo A (2007) CST Curation Set: 2564; Year: 2007; Biosample/Treatment: cell line, C2C12-D/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Guo A (2007) CST Curation Set: 2565; Year: 2007; Biosample/Treatment: cell line, C2C12-D/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Wiesner S, et al. (2006) A change in conformational dynamics underlies the activation of Eph receptor tyrosine kinases. EMBO J 25, 4686-96
16977320   Curated Info

8

Zhang G, Spellman DS, Skolnik EY, Neubert TA (2006) Quantitative phosphotyrosine proteomics of EphB2 signaling by stable isotope labeling with amino acids in cell culture (SILAC). J Proteome Res 5, 581-8
16512673   Curated Info

9

Dalva MB, et al. (2000) EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 103, 945-56
11136979   Curated Info

10

Binns KL, et al. (2000) Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol 20, 4791-805
10848605   Curated Info

11

Zisch AH, et al. (2000) Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene 19, 177-87
10644995   Curated Info